Publications by authors named "A Easson"
Background: Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.
View Article and Find Full Text PDFObjective: Stage 3 patients with clinically positive nodal metastasis are treated with therapeutic neck dissection and adjuvant systemic therapy. The aim of our study was to examined the predictability of pre-operative CT as a nodal drainage assessment tool.
Methods: Retrospective review of all patients with clinically positive head and neck cutaneous melanoma between 2010 and 2019.
Background: Visualization of cancer during breast conserving surgery (BCS) remains challenging; the BCS reoperation rate is reported to be 20-70% of patients. An urgent clinical need exists for real-time intraoperative visualization of breast carcinomas during BCS. We previously demonstrated the ability of a prototype imaging device to identify breast carcinoma in excised surgical specimens following 5-aminolevulinic acid (5-ALA) administration.
View Article and Find Full Text PDFArticle Synopsis
- * A multicenter clinical trial called PLAN will study the effects of intravenous lidocaine versus a placebo in over 1,600 patients undergoing breast cancer surgery, measuring outcomes like persistent pain incidence and opioid use at various time points post-surgery.
- * If successful, the trial could establish lidocaine infusion as a standard treatment to reduce chronic pain and opioid reliance in breast cancer patients, potentially lowering healthcare costs and improving overall patient well-being.
The innate lymphoid cell (ILC) family is composed of heterogeneous innate effector and helper immune cells that preferentially reside in tissues where they promote tissue homeostasis. In cancer, they have been implicated in driving both pro- and anti-tumor responses. This apparent dichotomy highlights the need to better understand differences in the ILC composition and phenotype within different tumor types that could drive seemingly opposite anti-tumor responses.
View Article and Find Full Text PDF